Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis

Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS). In this 3-year lo...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Multiple sclerosis Ročník 25; číslo 2; s. 196
Hlavní autoři:	Bsteh, Gabriel, Hegen, Harald, Teuchner, Barbara, Amprosi, Matthias, Berek, Klaus, Ladstätter, Felix, Wurth, Sebastian, Auer, Michael, Di Pauli, Franziska, Deisenhammer, Florian, Berger, Thomas
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.02.2019
Témata:	Adult Cognitive Dysfunction - etiology Disease Progression Female Humans Longitudinal Studies Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - complications Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - pathology Nerve Degeneration - diagnostic imaging Nerve Degeneration - pathology Prognosis Retina - diagnostic imaging Retina - pathology Tomography, Optical Coherence - methods Multiple sclerosis pRNFL disability progression cognitive decline optical coherence tomography
ISSN:	1477-0970, 1477-0970
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS). In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model. pRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT). Cross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice.
AbstractList	Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS).BACKGROUNDPeripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS).We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS).OBJECTIVEWe aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS).In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model.METHODSIn this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model.pRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT).RESULTSpRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT).Cross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice.CONCLUSIONCross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice. Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS). In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model. pRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT). Cross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice.
Author	Bsteh, Gabriel Amprosi, Matthias Ladstätter, Felix Deisenhammer, Florian Wurth, Sebastian Di Pauli, Franziska Teuchner, Barbara Berek, Klaus Hegen, Harald Auer, Michael Berger, Thomas
Author_xml	– sequence: 1 givenname: Gabriel surname: Bsteh fullname: Bsteh, Gabriel organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 2 givenname: Harald surname: Hegen fullname: Hegen, Harald organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 3 givenname: Barbara surname: Teuchner fullname: Teuchner, Barbara organization: Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 4 givenname: Matthias surname: Amprosi fullname: Amprosi, Matthias organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 5 givenname: Klaus surname: Berek fullname: Berek, Klaus organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 6 givenname: Felix surname: Ladstätter fullname: Ladstätter, Felix organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 7 givenname: Sebastian surname: Wurth fullname: Wurth, Sebastian organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 8 givenname: Michael surname: Auer fullname: Auer, Michael organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 9 givenname: Franziska surname: Di Pauli fullname: Di Pauli, Franziska organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 10 givenname: Florian surname: Deisenhammer fullname: Deisenhammer, Florian organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 11 givenname: Thomas surname: Berger fullname: Berger, Thomas organization: Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29095097$$D View this record in MEDLINE/PubMed
BookMark	eNpNkD1vFDEQhi0URJKDngpNmeYSf6zP5xJFCUSKlBRQn7y742TAay-2F2l_IX8L6whSqnk1fvzYes_ZSUwRGfso-KUQxlwJpWWn97rljkuxe8PORGfMllvDT17lU3Zeyg_OuTFKv2On0nKr28EZ-_OImWY3Uwgur5CxUnQBIubfCJ76jBDcihlcgQldWTKO0K-Q5kpDA4f0jBnjgFDTlJ6ym59XoAIO5pyeYioNg57S5PLPZompQophBZ8yNLQcJf1SwYWSjtuhXaNK7fmRiuspUF2PsoylUIpAEaYlVJoDQhkC5lSovGdvfVPgh5e5Yd9vb75df93eP3y5u_58vx3UTtdtJ63zClFb5cUoFRfSoPFedFbtUSkrOHbSWb-TnfHKo_JOSz5wse-kHIXcsIt_3vajXwuWepioDNjai5iWchC2qaXa73RDP72gSz_heJgztRbWw__y5V-3xY4R
CitedBy_id	crossref_primary_10_4103_1319_4534_322604 crossref_primary_10_1016_j_msard_2024_105545 crossref_primary_10_3390_brainsci13040591 crossref_primary_10_1111_ene_15612 crossref_primary_10_1016_j_compbiomed_2021_104416 crossref_primary_10_1097_WNO_0000000000001280 crossref_primary_10_1136_jnnp_2024_334801 crossref_primary_10_1002_acn3_52279 crossref_primary_10_1007_s00415_022_11474_4 crossref_primary_10_1007_s10354_022_00925_2 crossref_primary_10_1093_brain_awac317 crossref_primary_10_1186_s42466_025_00421_z crossref_primary_10_1177_13524585241267257 crossref_primary_10_1177_13524585221138486 crossref_primary_10_3389_fnins_2021_761654 crossref_primary_10_1212_WNL_0000000000011788 crossref_primary_10_1080_08820538_2023_2293030 crossref_primary_10_1212_NXI_0000000000001018 crossref_primary_10_1177_13524585251332499 crossref_primary_10_1002_brb3_3009 crossref_primary_10_1007_s00415_022_11348_9 crossref_primary_10_1016_j_compbiomed_2020_104165 crossref_primary_10_1177_1352458518814113 crossref_primary_10_1212_NXI_0000000000200030 crossref_primary_10_1007_s12325_024_02902_0 crossref_primary_10_1177_1352458520935724 crossref_primary_10_3389_fneur_2021_608491 crossref_primary_10_1002_acn3_674 crossref_primary_10_3389_fneur_2022_814734 crossref_primary_10_3390_ijms24054375 crossref_primary_10_1124_pharmrev_124_001073 crossref_primary_10_1177_13524585231201093 crossref_primary_10_3390_biomedicines8110523 crossref_primary_10_1007_s00415_022_11449_5 crossref_primary_10_1111_ene_16529 crossref_primary_10_1016_j_arr_2024_102280 crossref_primary_10_17116_oftalma202414003159 crossref_primary_10_1111_ene_13897 crossref_primary_10_1212_WNL_0000000000200970 crossref_primary_10_1016_j_msard_2021_103420 crossref_primary_10_1080_14737175_2025_2506462 crossref_primary_10_1111_ene_13770 crossref_primary_10_1007_s10439_022_02930_3 crossref_primary_10_1002_widm_1506 crossref_primary_10_1111_ene_14421 crossref_primary_10_3389_fneur_2021_678735 crossref_primary_10_1155_2021_5573839 crossref_primary_10_2147_EB_S295610 crossref_primary_10_1080_08164622_2021_1947745 crossref_primary_10_1177_13524585251329800 crossref_primary_10_3390_jpm11121349 crossref_primary_10_1016_S1474_4422_22_00173_9 crossref_primary_10_1007_s10072_023_07110_2 crossref_primary_10_1038_s41433_017_0010_2 crossref_primary_10_1111_ene_14829 crossref_primary_10_1177_13524585251360972 crossref_primary_10_1111_ene_70081 crossref_primary_10_2217_nmt_2020_0049 crossref_primary_10_1177_1352458519838205 crossref_primary_10_3390_healthcare10081386 crossref_primary_10_1007_s10072_024_07897_8 crossref_primary_10_3390_biom11091342 crossref_primary_10_3390_s21217127 crossref_primary_10_1016_j_msard_2023_105413 crossref_primary_10_1016_j_msard_2025_106667 crossref_primary_10_1016_j_jns_2025_123401 crossref_primary_10_1177_13524585221097566 crossref_primary_10_1177_13524585231198760 crossref_primary_10_1002_acn3_70157 crossref_primary_10_1136_jnnp_2023_332332 crossref_primary_10_1177_1352458519882279 crossref_primary_10_1007_s00415_023_12075_5 crossref_primary_10_1038_s41467_024_49309_7 crossref_primary_10_3389_fneur_2022_953188 crossref_primary_10_1007_s00415_021_10469_x crossref_primary_10_1212_NXI_0000000000200416 crossref_primary_10_1177_2055217320966344 crossref_primary_10_3390_jcm10132892 crossref_primary_10_3389_fneur_2021_666868
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1177/1352458517740216
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1477-0970
ExternalDocumentID	29095097
Genre	Journal Article
GroupedDBID	--- -TM .2E .2F .2G .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31S 31U 31X 31Y 31Z 36B 39C 4.4 53G 54M 5VS 7X7 88E 8FI 8FJ 8R4 8R5 AABMB AABOD AACKU AACMV AACTG AADUE AAEJI AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAJPV AAKGS AANSI AAPEO AAPII AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAFQ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHFT ABHKI ABHQH ABIDT ABJIS ABJNI ABJZC ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNXM ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADSTG ADTBJ ADUCT ADUKL ADVBO ADYCS ADZYD ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFUIA AFVCE AFWMB AGHKR AGKLV AGNHF AGPXR AGQPQ AGWFA AGWNL AHDMH AHHFK AHMBA AIGRN AJABX AJEFB AJGYC AJMMQ AJSCY AJUZI AJVBE AJXAJ AJXGE ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKIIM BKNYI BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD BYIEH CAG CBRKF CCPQU CDWPY CFDXU CGR COF CORYS CQQTX CS3 CUTAK CUY CVF DB0 DC- DC0 DD- DD0 DE- DF0 DO- DOPDO DU5 DV7 DV9 D~Y EBS ECM EIF EJD EMOBN F5P FD6 FEDTE FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HVGLF HZ~ J8X K.F K.J K9- M0R M1P N9A NPM O9- P.B P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SASJQ SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM UKHRP XJT ZONMY ZPPRI ZRKOI ZSSAH 7X8 AJHME
ID	FETCH-LOGICAL-c365t-429af3ee593f1d230127e7ff14938e33910e42a9f6247f3fe3fa520c018422d12
IEDL.DBID	7X8
ISICitedReferencesCount	80
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000457648700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1477-0970
IngestDate	Sat Sep 27 16:54:23 EDT 2025 Mon Jul 21 06:05:56 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Multiple sclerosis pRNFL disability progression cognitive decline optical coherence tomography
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c365t-429af3ee593f1d230127e7ff14938e33910e42a9f6247f3fe3fa520c018422d12
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	29095097
PQID	1959323865
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1959323865 pubmed_primary_29095097
PublicationCentury	2000
PublicationDate	2019-02-00 20190201
PublicationDateYYYYMMDD	2019-02-01
PublicationDate_xml	– month: 02 year: 2019 text: 2019-02-00
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Multiple sclerosis
PublicationTitleAlternate	Mult Scler
PublicationYear	2019
SSID	ssj0007735
Score	2.519358
Snippet	Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). We aimed to prospectively... Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS).BACKGROUNDPeripapillary...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	196
SubjectTerms	Adult Cognitive Dysfunction - etiology Disease Progression Female Humans Longitudinal Studies Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - complications Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - pathology Nerve Degeneration - diagnostic imaging Nerve Degeneration - pathology Prognosis Retina - diagnostic imaging Retina - pathology Tomography, Optical Coherence - methods
Title	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis
URI	https://www.ncbi.nlm.nih.gov/pubmed/29095097 https://www.proquest.com/docview/1959323865
Volume	25
WOSCitedRecordID	wos000457648700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3BbtQwELUKRagXKAVKKa0GqdeoG9sbxyeEqlYc6GoPIO1t5SQesVJrh02KtF_Y32Im8bInJCQuOURJlHgmnjczb2aEuCgVlsr5IitsZTNOOWaVRJMhVjzspdZ-LBT-amazcrGw8xRw6xKtcrsnDht1E2uOkV9yExQleULlp_ZnxlOjOLuaRmg8EfuKoAxTusxi1y3cmGHAZq6NySbWTHZpysucgIfmlBjBHzJzxd8B5mBobl7-7yseihcJYsLnUSdeiT0fjsTz25REfy0e56R1rWt53tB6A1zGyNcH5j4Ckvvs4c4REgfXwf0YQmyg2kBsh7g31PHHWCMIfbxPHa9h1YEDJnuFyJ2fgcv6mfmzhhB7iOFuAwSPoU1qAdVDD6T5cTj7h8METWr522-Gh40k3QCrAFvmI3T0UWTaV90b8f3m-tvVlyzNc8hqVUx70gTrUHlPq4R5Q75PLo03iOSkqdIrRcjFa-ksFlIbVOgVuqmc1BPyQqVscvlWPA0x-HcCmkrXhSQ7o7DWWsnKN0qiq2yOZqqL8kR83IpoSf8LJ0Fc8PGhW-6EdCKORzkv27Gxx1JaApykKO__4e5TcUDYyY4E7g9iH2nN_Jl4Vv_qV936fFBEOs7mt78BWTLtpw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Peripapillary+retinal+nerve+fibre+layer+as+measured+by+optical+coherence+tomography+is+a+prognostic+biomarker+not+only+for+physical+but+also+for+cognitive+disability+progression+in+multiple+sclerosis&rft.jtitle=Multiple+sclerosis&rft.au=Bsteh%2C+Gabriel&rft.au=Hegen%2C+Harald&rft.au=Teuchner%2C+Barbara&rft.au=Amprosi%2C+Matthias&rft.date=2019-02-01&rft.eissn=1477-0970&rft.volume=25&rft.issue=2&rft.spage=196&rft_id=info:doi/10.1177%2F1352458517740216&rft_id=info%3Apmid%2F29095097&rft_id=info%3Apmid%2F29095097&rft.externalDocID=29095097
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon